Sellas Life Sciences Shares Surge on Encouraging Clinical Trial Data

Shares of Sellas Life Sciences are posting significant gains in today’s trading session. This upward momentum follows the release of compelling clinical trial results for the company’s drug candidate, SLS009, presented at the annual meeting of the American Society of Hematology (ASH). The data, drawn from a Phase 2 study targeting an aggressive form of acute myeloid leukemia (AML), has resonated strongly with the investment community.

A Closer Look at the Trial Outcomes

The investigational therapy, SLS009, is a highly selective CDK9 inhibitor evaluated in combination with standard treatments. Within the trial cohort of patients with relapsed or refractory AML, the regimen demonstrated a robust overall response rate of 46%. Notably, nearly one-third of evaluable patients achieved a complete remission. These figures are particularly impactful as they pertain to a patient population with a historically very poor prognosis.

A critical breakthrough observed in the study relates to patient survival. In the cohort with the least prior treatment, the median overall survival reached 8.9 months. This result marks a substantial improvement over the historical benchmark of approximately 2.5 to 2.6 months for this specific subgroup. Furthermore, the treatment combination was reported to be well-tolerated, with no dose-limiting toxicities or treatment-related fatalities recorded.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

Broader Therapeutic Potential and Market Reaction

The encouraging efficacy signals were not confined to the overall study group. SLS009 also exhibited clinically meaningful activity in high-risk patients carrying unfavorable genetic mutations, such as ASXL1 and TP53. Building on these outcomes, Sellas Life Sciences has outlined plans to expand the trial to include newly diagnosed high-risk AML patients in the first quarter of 2026. This strategic move highlights the drug candidate’s potential across a wider therapeutic landscape.

The market has responded positively to this news flow. On Monday, the company’s stock price advanced by 4.6% to $1.82, accompanied by higher-than-average trading volume. Investor sentiment has shifted notably toward an “extremely bullish” stance. While technical indicators present a mixed picture, a buy signal from early December has already preceded a share price increase of more than 30%. Analysts project a fair opening price for today’s session at $1.86.